The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
@Stumbler - Submitted :)
The licence deal will happen i think in some kind of format for VAL 301.. matter of time...
Stumbler - very clever ;-)
Hi Porkie; one thing I should be grateful if you could ask "Are quantities still bein sent to Japan, for testing by the unknown Company?".
Bluecity you sound very familiar....hmmmmm hahaha good to have you back old bean!
Morning all
It’s going to be a lovely sunny blue day.
Porky thank you. Can you ask her if she will be sharing details of the work done with PYC through an RNS and the potential for treatment for Sepsis and Coronavirus or other cancers through this work and that the project does not need an extension and should shortly be finished. Also any positive findings regarding 201 with the work done by PYC that would increase the value of the drug?
It's clear we are reaching a point where a deal has to come or a placing and it has already been stated we will not get a placing. I stick with my September prediction for a deal for 201 and possibly next week before the meeting would make sense.
Nice questions there Porky. I'm sending through a couple myself:
1. So Suzy. I hear you're our saviour and that our bank accounts are going to be flooded soon with lots of beautiful money. Could you give me a rough idea on when this will happen? PM keeps telling me any day now, but I've recently just bought 8 Alpacas, 5 Siberian donkeys, a Welsh border collie pup and Red Rums great great great grandaughter on finance. We're currently all sharing a two bed flat in the centre of Derby, so really need to know when I can put my deposit in for the Dorset farm I found on rightmove.
2. This latest RNS says we're looking at a new novel technology in a London university to treat breast cancer. How is this progressing and will there be a partnering any day now for this?
3. I hear Kevin and A1 are starting to meet and spot each others lifts in the local Puregym just off the A444 ring road. A1 keeps telling me Kev's form is terrible and can barely squat 120kg, but I just don't see it. Kevin, could you respond to these wild accusations?
I have just added my first four questions to the Q & A section for the Investor Meets presentation. Obviously will likely add others closer to the event.
Happy to add other Investor Questions IF anyone here wants to know something about the company but unable to make the actual event or able to get involved.
Good Luck All:-
1. Obviously its key for shareholders that the company break the current never-ending cycle of raise, spend, raise spend historically continually eroding Shareholder value. Would you be able to confirm that the company has a clear focus now on attempting to get at least one product line licensed before yet another capital raise?
2. Regarding a licensing deal what do you envisage this might look like? Are we talking a cash consideration upfront plus a percentage ongoing royalty?
3. Your installed running cost is in the region of £ 800,000 a year. Do you see this remaining the same or significantly increasing should you secure a license deal? Obviously, shareholders would be delighted if you could expand the number of projects but only once you have at least one license deal secured to support expansion without a capital raise.
4. ICR analysis shows there have historically been more drug authorisations for blood and Breast Cancer which are quicker to license than for harder to treat cancers relating to the brain, oesophageal, bladder or the womb which typically take much longer. There was only one for liver cancer. Are you predominantly focusing attention on the seeking projects in the easier and quicker to license fields or do you have any plans to mix in some of the more challenging cancer fields?